T1	Participants 39 76	women with and without heart disease:
T2	Participants 267 272	women
T3	Participants 540 592	women with a history of coronary heart disease (CHD)
T4	Participants 624 663	tamoxifen in women with and without CHD
T5	Participants 919 967	13 388 women at increased risk for breast cancer
T6	Participants 1098 1147	13 194 women, 1048 of whom had prior clinical CHD
T7	Participants 1512 1572	women without CHD (6074 on tamoxifen versus 6072 on placebo)
